Accessibility Menu
AbCellera Biologics logo

AbCellera Biologics(NASDAQ) ABCL

Market Cap$2.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-84%
5 Year-39%
1 Year+120%
1 Month+37%
$9.33
+34.63%
+2.40Today
Pre market$9.27-$0.06 (-0.64%)
AbCellera Biologics last closing stock price
MetricPriceDate
Last closeUSD 9.342026-08-10
AbCellera Biologics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+60.21%USD 5.832026-08-03
1 month+37.35%USD 6.802026-07-10
3 month+88.69%USD 4.952026-05-12
Year to date+173.1%USD 3.422025-12-31
1 year+119.76%USD 4.252025-08-08
3 year+62.15%USD 5.762023-08-11
5 year-38.87%USD 15.282021-08-11
Since inception-84.14%USD 58.902020-12-11

AbCellera Biologics Financials at a Glance

Market Cap

$2.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$66.17M

Net Income (TTM)

-$164.66M

EPS (TTM)

-$0.54

P/E Ratio

-17.15

Dividend

$0.00

Beta (Volatility)

1.44 (Average)

Price

$9.33

Volume

150,895.655

Open

$8.76

Previous Close

$9.34

Daily Range

$8.40 - $10.01

52-Week Range

$2.75 - $10.01

Estimated Earnings Date

Nov 5, 2026

ABCL News

Financial Technologies - binary code background with dollar banknotes

How to Invest Like Peter Thiel

Jon QuastMay 1, 2026
pensive-invetor-getty

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

Cory RenauerJul 21, 2024
investor-looks-worried-at-computer-in-a-living-room-setting-getty

Down 57%, Is AbCellera Biologics a Buy on the Dip?

Cory RenauerJun 13, 2024
growth chart

3 Growth Stocks That Could Go Parabolic in 2024

George Budwell, PhDJan 15, 2024
health monitoring getty

1 Sector Received $6.1 Billion in AI Investments Last Year: 3 Top Stocks to Buy

Keith SpeightsApr 13, 2023
rising chart break through screen

Why AbCellera Biologics Rallied as Much as 24% on Wednesday

James BrumleyAug 10, 2022
falling chart on chalk board

Why AbCellera Biologics Is 10% Lower Today

James BrumleyMay 11, 2022
A syringe going into a vial.

Why AbCellera Biologics Stock Sank 21.6% in October

Keith NoonanNov 4, 2021
Page 1

ABCL: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AbCellera Biologics

AbCellera Biologics Inc. is a biotechnology company revolutionizing antibody drug discovery and development through a proprietary technology platform. By leveraging cutting-edge integrations of high-throughput microfluidics, genomics, and machine learning, AbCellera accelerates the identification and screening of therapeutic antibodies. This approach drastically reduces the time and cost compared to traditional methods, offering a competitive edge. With strategic partnerships across the pharmaceutical industry and a focus on expanding technological capabilities, AbCellera aims to streamline and enhance the drug discovery process.

Products and Services

Antibody drug discovery platform combining microfluidics, genomics, and machine learning.

Strategic partnerships with pharmaceutical companies for antibody development.

Development of a diversified portfolio of royalty and milestone-based programs.

Internal programs focusing on first-in-class and best-in-class antibody therapeutics.

Innovative therapeutic developments in areas like T-cell engagers and infectious diseases.

What Makes AbCellera Biologics Inc. Special

AbCellera stands out due to its integrated platform that accelerates antibody discovery and development, significantly reducing cost and time. Strategic partnerships further amplify its impact, offering a diversified revenue model while minimizing risks associated with solitary drug development efforts.

Five Things You Need to Know

AbCellera's platform integrates high-throughput microfluidics and machine learning for rapid antibody identification.

The company partners with pharmaceutical giants, leveraging collaborative research and development efforts.

Over 200 programs are under contract with 46 unique partners, enhancing its portfolio diversity.

AbCellera focuses heavily on R&D and has developed three specific technology platforms for therapeutic innovation.

With approximately $1 billion in available liquidity, the company is well-funded to execute its long-term strategic goals.

AI Generated • Apr 16, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

562

CEO

Carl Lars G. Hansen, PhD

Website

www.abcellera.com

Headquarters

Vancouver, BC V5Y 1G6, CA

ABCL Financials

Key Financial Metrics (TTM)

Gross Margin

74.95%

Operating Margin

-340.25%

Net Income Margin

-248.83%

Return on Equity

-17.49%

Return on Capital

-19.56%

Return on Assets

-12.59%

Earnings Yield

-5.83%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

306.61M

Volume

150.90K

Avg. Volume

7.80M

Financials (TTM)

Gross Profit

$49.60M

Operating Income

-$225.16M

EBITDA

-$160.30M

Operating Cash Flow

-$154.72M

Capital Expenditure

-$24.73M

Free Cash Flow

-$179.46M

Cash & ST Invst.

$540.10M

Total Debt

$135.62M

AbCellera Biologics Performance Analysis

AbCellera Biologics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 485,424,00029.4%
20232023-12-31USD 38,025,000-92.2%
20242024-12-31USD 28,833,000-24.2%
20252025-12-31USD 75,128,000160.6%
AbCellera Biologics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-47.6%
Q42025-12-31400.9%
Q12026-03-31-81.5%
Q22026-06-30-51.3%
AbCellera Biologics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.504.4%
20232023-12-31USD -0.51N/A
20242024-12-31USD -0.559.3%
20252025-12-31USD -0.49-11.4%
AbCellera Biologics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-58.3%
Q42025-12-3184.2%
Q12026-03-31-366.7%
Q22026-06-30-28.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$4.05M

-76.3%

Gross Profit

$4.05M

-76.3%

Gross Margin

100.00%

N/A

Market Cap

$2.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.10M

N/A

Employees

562

N/A

Net Income

-$55.43M

-59.6%

EBITDA

-$41.53M

-6.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$540.10M

-2.3%

Total Debt

$135.62M

-4.5%

Accounts Receivable

$95.43M

-37.8%

Inventory

$7.58M

N/A

Long Term Debt

$129.95M

-5.3%

Short Term Debt

$5.67M

+15.8%

Return on Assets

-12.59%

N/A

Return on Invested Capital

-17.95%

N/A

Free Cash Flow

-$36.00M

+21.4%

Operating Cash Flow

-$33.86M

-4.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLDXCelldex Therapeutics, Inc.
$42.97+3.02%
IMNMImmunome, Inc.
$25.69+2.64%
PHVSPharvaris N.V.
$34.84-0.20%
NUVBNuvation Bio Inc.
$6.60+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$97.52-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.80-0.01%
NVDANvidia
$217.55-0.03%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$37.73+0.01%

Questions About ABCL

What is the current price of AbCellera Biologics?

AbCellera Biologics is trading at $9.34 per share.

What is the 52-week range for AbCellera Biologics?

Over the past 52 weeks, AbCellera Biologics has traded between $2.75 and $10.01.

How much debt does AbCellera Biologics have?

As of the most recent reporting period, AbCellera Biologics reported total debt of $135.62M.

How much cash does AbCellera Biologics have on hand?

AbCellera Biologics reported $145.07M in cash and cash equivalents in its most recent financial results.

What is AbCellera Biologics’s dividend yield?

AbCellera Biologics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services